國家衛生研究院 NHRI:
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 908267      在线人数 : 972
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧:
  • 您可在西文检索词汇前后加上"双引号",以获取较精准的检索结果
  • 若欲以作者姓名搜寻,建议至进阶搜寻限定作者字段,可获得较完整数据
  • 进阶搜寻
    主页登入上传说明关于NHRI管理 到手机版

    子类别

    專利 [0/18]
    期刊論文 [157/157]
    會議論文/會議摘要 [23/37]

    邻近社群


    伍素瑩 [52/65]
    其他 [58/60]
    夏克山 [76/98]
    岳嶽 [29/32]
    張仲明 [7/9]
    張俊彥 [18/18]
    張竣評 [21/26]
    徐祖安 [170/215]
    李秀珠 [75/105]
    李靜琪 [23/24]
    林書玉 [19/20]
    洪明秀 [31/40]
    潘秀玲(2009-2013) [16/17]
    王文傑 [13/15]
    王鴻俊 [7/7]
    石全(2014-2017) [35/39]
    童俊維 [23/23]
    紀雅惠 [21/25]
    翁紹華 [22/24]
    莊宏 [1/1]
    葉修華 [24/25]
    葉燈光 [133/152]
    蔣維棠 [41/66]
    謝興邦 [171/231]
    趙宇生(2002-2013) [120/212]
    郭靜娟 [49/55]
    鄒倫 [28/29]
    陳志豪 [31/52]
    陳新(2002-2015) [53/67]
    顏婉菁 [6/7]
    許明珠(1997-2001) [3/10]
    陳淑貞(1998-2001) [3/11]
    陳華鍵(1997-2001) [9/9]

    社群统计


    近3年内发表的文件:19(8.96%)
    含全文笔数:180(84.91%)

    文件下载次数统计
    下载大于0次:180(100.00%)
    下载大于100次:176(97.78%)
    全文下载总次数:97565(1.82%)

    最后更新时间: 2024-12-01 08:26

    上传排行

    数据加载中.....

    下载排行

    数据加载中.....

    RSS Feed RSS Feed
    跳至:
    或输入年份:
    由新到旧排序 由最旧的开始

    显示项目76-100 / 212. (共9页)
    << < 1 2 3 4 5 6 7 8 9 > >>
    每页显示[10|25|50]项目

    日期题名關聯
    2016-12 Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation Oncotarget. 2016 Dec;7(52):86239-86256.
    2016-12 Novel cKIT kinase inhibitor, BPRCKJ001, as an advanced therapeutic candidate for GIST Annals of Oncology. 2016 Dec;27(Suppl. 9):Meeting Abstract 2P.
    2016-10 BPR1J373, an oral multiple tyrosine kinase inhibitor, targets c-KIT for the treatment of c-KIT driven myeloid leukemia Molecular Cancer Therapeutics. 2016 Oct;15(10):2323-2333.
    2016-10 Multifunctional nanoparticles for oral protein drug delivery Diabetes Research and Clinical Practice. 2016 Oct;120(Suppl. 1):S19.
    2016-08 Dipeptidyl peptidase-4 inhibitor LAF-237 improves glucose tolerance and expends graft beta cell mass in diabetic mice transplanted with a sufficient number of islets Diabetologia. 2016 Aug;59(Suppl. 1):S198.
    2016-05 N-Indolylglycosides bearing modifications at the glucose C6-Position as Sodium-Dependent Glucose Co-transporter 2 inhibitors Bioorganic and Medicinal Chemistry. 2016 May;24(10):2242-2250.
    2016-02 Multifunctional nanoparticles for oral protein drug delivery Nanomedicine: Nanotechnology, Biology and Medicine. 2016 Feb;12(2):463.
    2015-09 Self-assembling bubble carriers for oral protein delivery Biomaterials. 2015 Sep;64:115-124.
    2015-08 Novel Nrf2/ARE activator, trans-coniferylaldehyde, induces a HO-1-mediated defense mechanism through a dual p38alpha/MAPKAPK-2 and PK-N3 signaling pathway Chemical Research in Toxicology. 2015 Aug ;28(9):1681-1692.
    2015-08 Zinc-dipicolylamine directed pharmaceutical delivery system (ZAPS) as an innovative cancer drug delivery platform Cancer Research. 2015 Aug;75(Suppl. 15):Abstract number 4413.
    2015-08 Optimization of quinazoline-based kinase inhibitors: Identification of a dual FLT3/AURKA kinase inhibitor for the treatment of acute myeloid leukemia Abstracts of Papers of the American Chemical Society. 2015 Aug;250:Meeting Abstract 490.
    2015-07 Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations European Journal of Medicinal Chemistry. 2015 Jul;100:151-161.
    2015-04 IL-1beta promotes malignant transformation and tumor aggressiveness in oral cancer Journal of Cellular Physiology. 2015 APR;230(4):875-884.
    2015-03 Stem cell mobilizers targeting chemokine receptor CXCR4: Renoprotective application in acute kidney injury Journal of Medicinal Chemistry. 2015 Mar;58(5):2315-2325.
    2014-11 Discovery of multiple kinases inhibitors, DBPR114, as the novel anti-cancer agent European Journal of Cancer. 2014 Nov;50(Suppl. 6):92-93.
    2014-10 YYEI motif is critical to oncogenicity of 14-3-3 proteins Cancer Research. 2014 Oct;74(19 Suppl.):Abstract No. 3527.
    2014-10 Novel irreversible EGFR tyrosine kinase inhibitor, DBPR112, as a therapeutic candidate for lung adenocarcinoma Cancer Research. 2014 Oct;74(19 Suppl.):Abstract No. 1756.
    2014-08-15 Anticancer oral formulation 特許第5596680號/2014-08-15
    2014-08-04 Effects of dipeptidyl peptidase-4 inhibition with MK-0431 on syngeneic mouse islet transplantation International Journal of Endocrinology. 2014 Aug 4;2014:Article ID 795283.
    2014-06-04 抗癌口服制剂 ZL200980126979.4/2014-06-04
    2014-04 Treatment of chemotherapy-induced neutropenia in a rat model by using multiple daily doses of oral administration of G-CSF-containing nanoparticles Biomaterials. 2014 Apr;35(11):3641-3649.
    2014-03 DBPR112, a potent and selective EGFR kinase inhibitor in preclinical study Abstracts of Papers - American Chemical Society. 2014 Mar;247:Article number 315-MEDI.
    2014-01-08 Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer PLoS ONE. 2014 Jan 8;9(1):Article number e83160.
    2013-11 BPR0C305, an orally active microtubule-disrupting anticancer agent Anticancer Drugs. 2013 Nov;24(10):1047-1057.
    2013-11 A development drug candidate targeting EGFR kinase for lung cancer: DBPR112 Journal of Thoracic Oncology. 2013 Nov;8(Suppl. 2):S779-S780.

    显示项目76-100 / 212. (共9页)
    << < 1 2 3 4 5 6 7 8 9 > >>
    每页显示[10|25|50]项目

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈